Panacea Venture is a healthcare venture fund with global vision and reach dedicated to transforming lives through promising innovation.

Panacea Venture

Panacea Venture is a life sciences venture capital firm with global vision and presence across three continents. The firm was founded in 2017 and is currently managing four funds investing in early-stage companies through public investments. Panacea incubates early-stage companies with breakthrough technologies and discoveries that can potentially address unmet medical needs to enhance quality of life on a global scale. The investment team has more than 100 years of combined investing experience and, along with venture partners and advisors, provides broad coverage across emerging and established biotech, diagnostic and medtech sectors. In addition, Panacea’s highly experienced team has a strong track record navigating portfolio companies to success.  

New Amsterdam Pharma

Johnson & Johnson Innovation – JLABS recognizes that unlocking investment opportunities is every start-up's biggest challenge and continue facilitating connections between regional and global investment funds and Singapore’s life-science ecosystem.
 
On August 29, JLABS will introduce Panacea Venture at the stunning co11ab Novena in Singapore! Our Founder and Managing Partner, James Huang brings an impressive background as an investor, entrepreneur, and corporate experience at companies previously acquired by big pharma. There will also be a star panel discussion featuring distinguished industry experts alongside James, including Yue (Shelby) Zhang and David M Epstein being moderated by JLABS Ronne Yeo

#biotech #investing #JLABS #lifesciences

We are pleased to announce that the Investigational New Drug (“IND”) application of Cyclosporine A (“CsA”) Ophthalmic Gel for the treatment of moderate to severe dry eye disease (“DED”) has been approved by the National Medical Products Administration (the “NMPA”) of China.  This Phase III clinical trial has been designed to closely follow the requirements outlined by the Center for Drug Evaluation (the “CDE”) in its Technical Guidelines on Clinical Trials for Therapeutic Drugs for Dry Eyes issued in September 2023.
 
We are also pleased to announce that on 5 August 2024, the last patient last visit was completed for the two-year Phase III clinical trial (“China CHAMP”) of our core product NVK002, a treatment for myopia progression control. 

For more information, please visit:
https://lnkd.in/d5M8H4hA

#zhaoke #ophthalmology #healthcare #eyecare #pharmaceutical #biotech #dryeye #myopia

Congratulations to Human Longevity for completing Series B financing further supporting their efforts of developing innovative solutions to help people live longer, healthier lives!

Thank you Human Longevity, Inc. for inviting me to give a keynote on the latest advancements in #longevitymedicine. Tailoring the interventions to an individual is crucial for maximizing their effectiveness. Honored to talk more about it on July 10th.
#longevityphyscian #healthylongevity

link: https://lnkd.in/d6gqpSgG

The FDA’s official press release regarding the START Pilot Program includes Myrtelle as 1 of 4 CBER participants. Read the full article below! #fda #STARTProgram #myrtelle
https://bit.ly/3zoOecV

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Aug 31, 2024 1:29 AM	96f6820c
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	dfa1501c
crunchbase profile	general
li profile	general	Aug 31, 2024 1:29 AM	b8311902
translate crunchbase fundingrounds	general
peers	general	Aug 31, 2024 1:29 AM	ba766d5d
news basic	general	Aug 31, 2024 1:29 AM	b213e51f
bundesanzeiger	filings
financials download nd	financials
private financials	financials

PANA

COM:PANACEAVENTURE

Panacea Venture